Medica 2010 - November 17-20, 2010, Düsseldorf, Germany
Inbios News
Sandfly Fever (Papatasi) Virus
July 08, 2008
InBios has received a Phase II SBIR contract from the Dept. of Defense (Army) to develop a point-of-care differential diagnostic test to discriminate between sandfly fever virus infection (Papatasi virus) and Leishmaniasis in sandflies. This award is a competitive renewal of the Phase I contract obtained in 2007. Supported by the US Army Medical Research and Materiel Command under Contract No. W81XW14-7282M386.
Rickettsia Infection
July 08, 2008
InBios has received a Phase II SBIR contract from the Dept. of Defense (Army) to develop a lateral flow-based differential diagnostic test that will discriminate between spotted fever group rickettsial infection and typhus group organisms. This award is a competitive renewal of the Phase I contract obtained in 2007. Supported by the US Army Medical Research and Materiel Command under Contract No. A2-3258.
Sandfly Fever (Papatasi) Virus
October 15, 2007
InBios has received a Phase I SBIR contract from the Dept. of Defense (Army) to develop a point-of-care differential diagnostic test to discriminate between sandfly fever virus infection (Papatasi virus) and Leishmaniasis directly in sandflys which are the vectors of both diseases. In endemic areas, these diseases present with similar symptoms. Supported by the US Army Medical Research and Materiel Command under Contract No. A072-150-0023
Rickettsia Infection
October 15, 2007
InBios has received a Phase I SBIR contract from the Dept. of Defense (Army) to develop a lateral flow-based differential diagnostic test that will discriminate between spotted fever group rickettsial infection and typhus group organisms. Supported by the US Army Medical Research and Materiel Command under Contract No. A072-153-0025.
Dengue Fever*¶
September 01, 2007
InBios has received a two year, Phase I, SBIR award from NIAID’s advanced technology program to use microarrays to screen for novel antigens that will enable the rapid detection of infection by Dengue virus.
Necrotizing Hepatopancreatitis Infection¶
September 01, 2007
InBios has received a two year, Phase II grant from the USDA to develop a test for the bacterium that causes necrotizing hepatopancreatitis infection in farmed shrimp in the Americas. This grant is a competitive renewal of the Phase I award received in 2005.
Enteric Pathogens
September 01, 2007
InBios has received a Phase II contract from the Dept. of Defense (Army) to develop a multiplexed rapid test for diarrhea causing enteric pathogens commonly found in military personnel. This award is a competitive renewal of the Phase I contract obtained in 2006. Supported by the US Army Medical Research and Materiel Command under Contract No. W81XWH-07C-C-0030.
Enteric Pathogens
November 13, 2006
InBios has received a Phase I SBIR contract from the Dept. of Defense to develop a multiplexed rapid test for enteric pathogens commonly found in soldiers deployed overseas. The pathogens include Salmonella, Shigella, E. coli O157, Campylobacter, Cryptosporidium, Norovirus and Rotavirus. This award greatly augments InBios’ ability to develop a portfolio of diagnostic assays for use in military and biodefense applications. Supported by the US Army Medical Research and Materiel Command under Contract No. W81XW-07-C-0030.
Brucellosis
September 01, 2006
InBios has received a Phase I SBIR grant from the NIH’s biodefense program to develop advanced assays for the detection of Brucella. This bacterium is the cause of Brucellosis and infects both farm animals and humans. Not only is the disease of major humanitarian and economic importance but Brucella is considered a serious biothreat agent. The work complements InBios’ R&D efforts in other areas of biodefense.
Cutaneous Leishmaniasis
February 01, 2006
InBios has received a Phase II SBIR contract from the Department of Defense to continue development of a test for identifying the causative agent of cutaneous Leishmaniasis in skin lesions of deployed troops. This award is a competitive renewal of a Phase I contact received in 2004. Supported by the US Army Medical Research and Materiel Command under Contract No. W81XWH-05-C-0018.
Fever Causing Organisms
January 30, 2006
InBios has received a Phase I SBIR contract from the Department of Defense to develop a multiplex test for fever causing organisms in deployed military personnel. The efficient diagnosis of diseases presenting with pyrogenic symptoms poses a considerable challenge to U.S armed forces medical staff in overseas postings, particularly the Middle East. InBios will address this problem by developing a unique lateral flow or dipstick test that capable of diagnosing, simultaneously, five common fever-causing pathogens, namely Salmonella sp., Leptospira sp., Rickettsia sp., Flaviviruses and Plasmodium (malaria). The development of such a rapid test will lead to the earlier diagnosis and treatment of these diseases. Supported by the US Army Medical Research and Materiel Command under Contract No. W81XWH-06-C-0095.
Melioidosis
September 01, 2005
InBios has received a Phase I Biodefense Grant from the NIH to identify novel antigens of Burkholderia pseudomallei, for use in diagnostic test development. The organism is the causative agent of melioidosis prevalent in Thailand, SE Asia, and Northern Australia. A recent surge of interest in this disease results from the increased number of cases due to the Tsunami in SE Asia. B. pseudomallei is also classed as a Category B biothreat agent.
Necrotizing Hepatopancreatitis Bacterium
May 19, 2005
InBios has received a Phase I SBIR grant from the USDA to develop a test for identifying the bacterium causing hepato-pancreatitis in cultured shrimp. This disease is a problem in shrimp aquaculture in both North and South America and has significant economic consequences. Identification of the disease through the use of a rapid test can lead to earlier treatment before the shrimp become lethargic and stop eating before antibiotic treatment can be administered. This is a niche product in an exciting new area for InBios.
Cutaneous Leishmaniasis
December 13, 2004
InBios has received a Phase 1 SBIR contract from the Department of Defense to develop a test for identifying the causative agent of cutaneous Leishmaniasis. This disease is a serious problem in Middle Eastern countries and there have been numerous outbreaks among U.S military personnel. The development of a test for the parasite Leishmania major and other leishmania parasites directly in skin lesions will lead to the earlier diagnosis and treatment of the disease. The test will also complement InBios's FDA approved test for visceral leishmaniasis. Supported by the US Army Medical Research and Materiel Command under Contract No. W81XWH-4322-M098.
510(k) Clearance
November 19, 2004
InBios has received 510(k) clearance from the Food and Drug Administration for its West Nile Detect IgM Capture ELISA. This in vitro diagnostic assay is highly sensitive and specific for the West Nile Virus. This kit is available to worldwide.
Chagas’ Disease
July 01, 2004
InBios has received a Phase II SBIR grant from NIH to develop a rapid immunoassay for Trypanosoma cruzi infection (Chagas’ disease). This disease is prevalent throughout Latin America and has occurred in the United States as well. The company intends to develop this test in an ELISA and immunoblot format as well. The company believes this test will complement its current product line of diagnostic tests for infectious diseases.
Visceral Leishmaniasis
September 15, 2002
A Phase II grant from NIAID to develop a rapid, point of care assay for visceral Leishmaniasis. This parasitic disease is a serious public health problem in the developing world and existing diagnostic assays are either too expensive or have poor sensitivity and specificity. This funding is in keeping with InBios’ commitment to develop high performance, low cost assays for the developing world.
All the above grants and contacts utilized recombinant DNA. In pursuit of these studies, InBios and its Investigators adhered to the National Institutes of Health (NIH) Guidelines for Research Involving Recombinant DNA Molecules; Notice, Federal Register, November 19, 2001, Volume 66, Number 223.
¶Studies marked thus above involved the use of animals. In conducting this research InBios and its Investigator(s) adhered to the Animal Welfare Act Regulations and other Federal statutes relating to animals and experiments involving animals and the principles set forth in the Guide for Care and Use of Laboratory Animals, National Research Council, 1996.
*Studies marked thus above involved the use of human subjects. In conducting this research InBios and its Investigator(s) adhered to the policies regarding the protection of human subjects as prescribed by Code of Federal Regulations (CFR) Title 45, Volume 1, Part 46; Title 32, Chapter 1, Part 219; and Title 21, Chapter 1, Part 50 (Protection of Human Subjects).